This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We greatly appreciate the insightful comments by Dr. Taccetta on our article.1 We agree that passive epidemiologic surveillance is less likely to detect incidence, which is why we only reported the observed incidence and not a rate or ratio. This is a limitation we acknowledged in our article.1 In addition, concerning the 30-day timeframe from immunization to event detection in our study, we recognize that some neurologic events such as cerebral venous thrombosis (CVT) and Guillain-Barré syndrome (GBS) may occur up to 42 days after immunization. However, as stated in the Methods section, the World Health Organization's noted operational definition for surveillance of adverse events following immunization (AEFI) in our country only includes events occurring within the first 30 days after immunization.2,3 Hence, we were unable to detect or collect data on those cases occurring beyond the time frame specified by our legislature—a limitation that we also acknowledged as a potential selection bias. Recently, the increasing number of vaccine-induced thrombotic thrombocytopenia with CVT and GBS reports worldwide, especially with adenovirus-based vaccines,4,5 has compelled the expansion of our country's AEFI surveillance time frame to consider cases occurring within the first 42 days. We plan to consider this information in future reports.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- Received August 12, 2022.
- Accepted in final form August 12, 2022.
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
